Form 4 for AKBA Akebia Therapeutics, Inc.
Accepted 2025-06-11 00:00:00 ET · period of report 2025-06-09 · accession 0001562180-25-004717 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2025-06-11 | 2025-06-09 | AKBA | Malabre Richard C | SVP, CAO | S - Sale+OE | $4.01 | -15.0K | 266.9K | -5% | -$60.1K |
| DT | 2025-06-11 | 2025-06-09 | AKBA | Malabre Richard C | SVP, CAO | M - OptEx | $1.68 | +15.0K | 281.9K | +6% | +$25.2K |
| DT | 2025-06-11 | 2025-06-09 | AKBA | Malabre Richard C | SVP, CAO | M - OptEx | $0.00 | -15.0K | 321.0K | -4% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-06-09 | S | D | 15,000 | $4.01 | 266,914 | D | — | — | (F2) This sale was made pursuant to a Rule 10b5-1 Non-Discretionary Option Exercise and Stock Sale Plan adopted by the reporting person on December 12, 2024. (F3) The shares were sold at prices ranging from $4.00 to $4.03 and the price reported reflects the weighted average sale price. |
| 2 | Common | Common Stock | 2025-06-09 | M | A | 15,000 | $1.68 | 281,914 | D | — | — | (F1) This stock option exercise was made pursuant to a Rule 10b5-1 Non-Discretionary Option Exercise and Stock Sale Plan adopted by the reporting person on December 12, 2024. |
| 3 | Derivative | Stock Option (Right to buy) | 2025-06-09 | M | D | 15,000 | $0.00 | 321,000 | D | $1.68 · — to 2034-01-31 | 15,000 Common Stock | (F1) This stock option exercise was made pursuant to a Rule 10b5-1 Non-Discretionary Option Exercise and Stock Sale Plan adopted by the reporting person on December 12, 2024. (F4) The options were granted by the Issuer as an inducement material to the reporting person's entering into employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date. |